Phenotyping Core

表型核心

• 批准号: 9924582
• 负责人: Lijun Xia
• 金额: $ 44.85万
• 依托单位: OKLAHOMA MEDICAL RESEARCH FOUNDATION
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9924582
• 关键词: Accountability; Advisory Committees; Biology; Blood; Blood Cell Count; Blood Cells; Blood Chemical Analysis; Blood Vessels; Cardiovascular Diseases; Cardiovascular system; Centers of Research Excellence; Chemicals; Chemistry; Clinical; Complex; Consultations; Disease; Disease model; Doctor of Medicine; Doctor of Philosophy; Effectiveness; Functional disorder; Funding; Future; Gene Targeting; Goals; Grant; Interdisciplinary Study; International; Leadership; Molecular; Mus; Pathology; Phase; Phenotype; Physicians; Pilot Projects; Procedures; Publications; Reporter; Research; Research Personnel; Research Project Grants; Resources; Sampling; Scientist; Services; Structure; Surveys; System; Technical Expertise; Techniques; Technology; Testing; Tissues; Training; Ultrasonography; Universities; Urine; automated analysis; cardiovascular imaging; catalyst; cost; design; experience; follow-up; genetic analysis; genetic resource; heart function; hemodynamics; imaging system; instrument; instrumentation; member; metabolic phenotype; mouse genetics; mouse model; novel; programs; recruit; response; skills; success; tool

PROJECT SUMMARY: The Cardiovascular Phenotyping Core was added during Phase II of the OMRF “Interdisciplinary Research in Vascular Biology” COBRE grant in response to growing demand from COBRE investigators for scientific and technical expertise in developing cardiovascular disease models and conducting specialized pathophysiological tests. The Phase III Cardiovascular Phenotyping Core objective is to expand resources, services, and training available to COBRE and non-COBRE investigators for establishing precise cardiovascular and metabolic phenotypes for their genetically-altered mice. All COBRE investigators use gene- targeted mice and mouse models of cardiovascular disease as major research approaches to elucidate the molecular mechanisms of disease and generate novel discoveries in cardiovascular biology. This year, we significantly strengthened the Core capabilities by purchasing a cutting-edge VisualSonics Vevo-2100 Ultrasound Imaging System. With institutional support, we upgraded our Hemavet analyzer for blood cell count and differentials, and purchased a new Catalyst Dx Chemistry Analyzer that permits automated analysis of a broad spectrum of clinical chemical parameters of mouse blood and urine samples. The Core will provide a centralized system for accessing this state-of-the-art technology for evaluating complex cardiovascular disease pathologies to COBRE and non-COBRE investigators and will be guided by 3 specific aims: 1) Provide services of echocardiographic and Doppler imaging of cardiovascular structures and functions of genetically modified mice using Vevo-2100 system; 2) Provide consultation, training, genetic resources, and special instrumentation for general phenotyping, including peripheral blood cell and chemistry analyses, and sophisticated mouse cardiovascular procedures/disease models. The Core will maintain colonies of valuable mouse genetic tools (e.g. inducible or tissue-specific Cre or reporter lines) for genetic analysis of cardiovascular phenotypes; 3) Develop Core into sustainable facility that continues to provide services to COBRE and external cardiovascular investigators after Phase III funding. To achieve the Aims, the Core will provide COBRE and external investigators: 1) direct ultrasound imaging services, 2) technical training to use validated cardiovascular phenotyping techniques and instruments, 3) service for procedures requiring highly specialized skills, and 4) mouse genetic tools. A Core Coordinator will be designated for service requests and conduct regular surveys of end users to evaluate quality, turn-around, service costs, and training effectivness: this will be evaluated quarterly by Core Directors and annually by the External Advisory Committee, providing accountability for the Core's success. The Aims will be implemented under highly qualified director/co-director leadership and dedicated expert technical staff. By offering unique training and collaborative opportunities, we expect to develop this Core into a sustainable facility and further nurture establishment of an internationally- recognized center of excellence.

项目摘要：在OMRF的II期中添加了心血管表型核心 “血管生物学的跨学科研究”毛茸茸的赠款响应着毛c的需求不断增长 开发心血管疾病模型和进行的科学技术专长研究者 专门的病理生理测试。 III期心血管表型核心目标是扩展 可用于山羊和非近代调查人员的资源，服务和培训，以建立精度 其一般改变的小鼠的心血管和代谢表型。所有毛to研究者都使用基因 靶向小鼠和心血管疾病的小鼠模型，作为阐明的主要研究方法 疾病的分子机制，并在心血管生物学中产生新发现。今年，我们 通过购买尖端的Visualsonics Vevo-2100，可以显着增强核心功能 超声成像系统。在机构支持的情况下，我们升级了血细胞计数的Hemavet分析仪 和差异，并购买了一种新的催化剂DX化学分析仪，该分析仪允许对 小鼠血液和尿液样品的临床化学参数的广泛谱。核心将提供 用于访问这种评估复杂心血管疾病的最先进技术的集中系统 对毛病和非近代研究人员的病理学，将由3个特定目的指导：1）提供 心血管结构的超声心动图和多普勒成像的服务以及一般的功能 使用VEVO-2100系统修饰的小鼠； 2）提供咨询，培训，遗传资源和特殊 用于一般表型的仪器，包括外周血细胞和化学分析，以及 复杂的小鼠心血管手术/疾病模型。核心将保持价值殖民地 小鼠遗传工具（例如诱导或组织特异性CRE或报告基因线）用于遗传分析 心血管表型； 3）将核心发展成可持续设施，该设施继续为 第三阶段资金后的毛病和外部心血管调查员。为了实现目标，核心将 提供山脉和外部调查人员：1）直接超声成像服务，2）使用技术培训 经过验证的心血管表型技术和仪器，3）需要高度要求的过程 专业技能和4）鼠标遗传工具。核心协调员将被指定为服务请求和 定期对最终用户进行调查，以评估质量，转弯，服务成本和培训有效性： 这将由核心董事每季度和外部咨询委员会每年评估 对核心成功的责任。该目标将在高素质的董事/联合导演下实施 领导力和专业技术人员。通过提供独特的培训和协作机会，我们 期望将此核心发展成可持续设施，并进一步建立国际 公认的卓越中心。